Immunic
IMUX
50 hedge funds and large institutions have $31.3M invested in Immunic in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 16 reducing their positions, and 15 closing their positions.
0% less ownership
Funds ownership: 0.07% → 0.06% (-0%)
6% less funds holding
Funds holding: 53 → 50 (-3)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
30% less capital invested
Capital invested by funds: $44.8M → $31.3M (-$13.5M)
38% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 16
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $17K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.38M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$856K |
| 3 |
Goldman Sachs
New York
|
+$563K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$455K |
| 5 |
ECM
Element Capital Management
New York
|
+$410K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.26M |
| 2 |
State Street
Boston,
Massachusetts
|
-$876K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$687K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$359K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$310K |
IMUX Hedge Fund Activity: Q2 2017 in Review
50 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q2 2017, worth a combined $31.3M — down 30% from $44.8M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of IMUX and 12 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 10 added.
The largest buyer was Millennium Management, adding an estimated $1.38M. The largest seller was BlackRock, cutting an estimated $3.26M.
- 50 institutional investors held Immunic (IMUX) as of Q2 2017, down from 53 in Q1 2017.
- Funds reported $31.3M of Immunic stock for Q2 2017, down 30% quarter-over-quarter.
- 12 funds opened new Immunic positions in Q2 2017 and 15 closed out, a net change of -3 holders.
- The largest Immunic buyer in Q2 2017 was Millennium Management, an estimated $1.38M added.
- The largest Immunic seller in Q2 2017 was BlackRock, an estimated $3.26M sold.
Based on aggregated 13F filings for Q2 2017.